Department of General Surgery 1, the Affiliated Hospital of Chengde Medical College, Chengde City, Hebei Province, China.
PLoS One. 2013 Aug 2;8(8):e71930. doi: 10.1371/journal.pone.0071930. Print 2013.
The prognostic significance of survivin for the survival of patients with gastric cancer remains controversial. Thus, the objective of this study was to conduct a systematic review of the literature evaluating survivin expression in gastric cancer as a prognostic indicator.
Relevant literature was searched using PubMed, EMBASE, and Chinese biomedicine databases. A meta-analysis of the association between survivin expression and overall survival in patients with gastric cancer was performed. Studies were pooled and summary hazard ratios (HRs) were calculated. Subgroup analyses were also conducted.
Final analysis of 1365 patients from 16 eligible studies was performed. Combined HR suggested that survivin expression had an unfavorable impact on survival of gastric cancer patients (HR=1.39, 95% CI: 1.16-1.68). The unfavorable impact also appeared significant when stratified according to the studies categorized by patients' ethnicity, detection methods, type of sample, and HR estimate. The combined HR in the English literature showed an inverse effect on survival (HR=1.40, 95% CI: 1.13-1.75), while HR in the non-English literature did not (HR=1.38, 95% CI: 0.93-2.05). When stratified according to the location of survivin expression, combined HR showed that expression in cytoplasm was significantly associated with poor prognosis of gastric cancer patients (HR=1.46, 95% CI: 1.12-1.90). While expression in nucleus was not significantly associated with poor prognosis (HR=1.29, 95% CI: 0.72-2.31), the heterogeneity was highly significant (chi-squared=11.5, I(2)=74%, p=0.009).
This study showed that survivin expression was associated with a poor prognosis in patients with gastric cancer. Cytoplasmic expression of survivin may be regarded as a prognostic factor for gastric cancer patients. In contrast, survivin expression in nucleus did not have a significant impact on patients' overall survival.
生存素对胃癌患者生存的预后意义仍存在争议。因此,本研究的目的是对评估生存素在胃癌中作为预后指标的表达的文献进行系统综述。
使用 PubMed、EMBASE 和中国生物医学数据库检索相关文献。对胃癌患者生存素表达与总体生存的相关性进行了meta 分析。对研究进行了合并,并计算了汇总风险比(HR)。还进行了亚组分析。
对 16 项合格研究中的 1365 名患者进行了最终分析。合并 HR 表明,生存素表达对胃癌患者的生存有不利影响(HR=1.39,95%CI:1.16-1.68)。根据患者种族、检测方法、样本类型和 HR 估计分类的研究进行分层时,这种不利影响也很明显。英文文献中的合并 HR 对生存有反向影响(HR=1.40,95%CI:1.13-1.75),而非英文文献中的 HR 则没有(HR=1.38,95%CI:0.93-2.05)。根据生存素表达位置进行分层时,合并 HR 表明细胞质表达与胃癌患者的预后不良显著相关(HR=1.46,95%CI:1.12-1.90)。而核内表达与预后不良无显著相关性(HR=1.29,95%CI:0.72-2.31),但异质性非常显著(chi-squared=11.5,I(2)=74%,p=0.009)。
本研究表明,生存素表达与胃癌患者的预后不良相关。生存素的细胞质表达可能被视为胃癌患者的预后因素。相反,核内生存素表达对患者的总体生存没有显著影响。